Why Sage Therapeutics Stock Is Tumbling Today
Shares of the brain-health specialist Sage Therapeutics (NASDAQ: SAGE) are having a tough trading session today. Specifically, the biotech's stock was down by approximately 13% on heavy volume as of 2:38 p.m. ET Wednesday afternoon.
The spark? Yesterday, (NASDAQ: BIIB) Chief Executive Officer Christopher Viehbacher barely mentioned the upcoming regulatory decision for zuranolone as a treatment for major depressive disorder (MDD) and postpartum depression (PPD). Biogen and Sage co-developed zuranolone as a fast-acting option for patients with these debilitating forms of depression. The Food and Drug Administration (FDA) is slated to hand down a regulatory decision in these two settings by Aug. 5.
Investors took Viehbacher's silence as a troubling sign that all is not well with zuranolone's regulatory review. Normally, labeling discussions are taking place at this late stage in a drug review. However, Biogen's leader didn't mention anything on the topic, leading some nervous investors to speculate that a regulatory delay, or an outright rejection, was on the way.
Source Fool.com
Biogen Inc. Aktie
Biogen Inc. sticht hervor mit 52 Buy- und nur 2 Sell-Einschätzungen.
Das Kursziel von 286 € für Biogen Inc. weist auf eine Steigerung von über 50% gegenüber dem aktuellen Kurs von 186.25 € hin.
